Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.73 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.73 |
| ▸ | FLT1 | P17948 | 4/20 | 0.73 |
| ▸ | VEGFA | P15692 | 4/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534193 | 0.87 | EGLN1 (0.82) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL20171231 | 0.86 | EGLN1 (0.72) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL1921954 | 0.85 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL1921875 | 0.82 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFA | |
| SCHEMBL13095627 | 0.77 | EGLN1 (0.84) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL20171244 | 0.74 | EGLN1 (0.76) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL1923183 | 0.74 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL20171240 | 0.74 | EGLN1 (0.55) | EGLN1EGLN3FLT1VEGFA | |
| SCHEMBL14308512 | 0.73 | EGLN1 (0.81) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL14308516 | 0.73 | EGLN1 (0.81) | EGLN1EGLN3FLT1VEGFAFTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357911-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3323807-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |